Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6446)
All Articles published online
|
Dec 21, 2011 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011; 17(47): 5166-5171 [PMID: 22215940 DOI: 10.3748/wjg.v17.i47.5166] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i47/5166.htm |
| Number | Citing Articles |
| 1 |
Kaija-Leena Kolho. Assessment of disease activity in pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2016; 10(10): 1127 doi: 10.1080/17474124.2016.1185364
|
| 2 |
KL Kolho, D. Turner, G. Veereman‐Wauters, M. Sladek, L. de Ridder, R. Shaoul, A. Paerregaard, J. Amil Dias, S. Koletzko, F. Nuti, Y. Bujanover, A. Staiano, K. Bochenek, L. Finnby, A. Levine, G. Veres. Rapid Test for Fecal Calprotectin Levels in Children With Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition 2012; 55(4): 436 doi: 10.1097/MPG.0b013e318253cff1
|
| 3 |
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine, Frank M Ruemmele. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 2021; 15(2): 171 doi: 10.1093/ecco-jcc/jjaa161
|
| 4 |
Anssi Hämäläinen, Taina Sipponen, Kaija-Leena Kolho. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2013; 48(1): 35 doi: 10.3109/00365521.2012.741619
|
| 5 |
Paul Henderson, Niall H Anderson, David C Wilson. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2014; 109(5): 637 doi: 10.1038/ajg.2013.131
|
| 6 |
Maija Piekkala, Henrik Alfthan, Laura Merras‐Salmio, Anne Puustinen Wikström, Kaarina Heiskanen, Tytti Jaakkola, Paula Klemetti, Martti Färkkilä, Kaija‐Leena Kolho. Fecal Calprotectin Test Performed at Home. Journal of Pediatric Gastroenterology and Nutrition 2018; 66(6): 926 doi: 10.1097/MPG.0000000000001861
|
| 7 |
George Vaos, Ioannis D. Kostakis, Nick Zavras, Athanasios Chatzemichael. The Role of Calprotectin in Pediatric Disease. BioMed Research International 2013; 2013: 1 doi: 10.1155/2013/542363
|
| 8 |
Maureen C. Turina, Robert Landewé, Dominique Baeten. Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. Expert Review of Clinical Immunology 2017; 13(4): 333 doi: 10.1080/1744666X.2017.1244004
|
| 9 |
Roberta Caccaro, Renata D’Incà, Surajit Pathak, Giacomo Carlo Sturniolo. Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature?. Expert Review of Clinical Immunology 2012; 8(6): 579 doi: 10.1586/eci.12.50
|
| 10 |
Sara Hone Lopez, Mathilde Jalving, Rudolf S.N. Fehrmann, Wouter B. Nagengast, Elisabeth G.E. de Vries, Jacco J. de Haan. The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment. Cancer Treatment Reviews 2022; 107: 102406 doi: 10.1016/j.ctrv.2022.102406
|
| 11 |
Yi Fengming, Wu Jianbing. Biomarkers of Inflammatory Bowel Disease. Disease Markers 2014; 2014: 1 doi: 10.1155/2014/710915
|
| 12 |
Liliana-Elisabeta David, Teodora Surdea-Blaga, Dan-Lucian Dumitrascu. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study. Sao Paulo Medical Journal 2014; 133(4): 343 doi: 10.1590/1516-3180.2014.8000815
|
| 13 |
Eileen Crowley, Anne M. Griffiths, Vipul Jairath, Dan Turner, Christopher Ma, Tran M. Nguyen, Hayley McKay, Rilla Schneider, Arielle Silverberg, Melanie Schmidt, Aleixo Muise, Brian G. Feagan. Heterogeneity in Efficacy and Safety Endpoints for Pediatric Clinical Trials in Inflammatory Bowel Disease: A Need for Harmonization. Gastroenterology 2022; 163(5): 1137 doi: 10.1053/j.gastro.2022.07.006
|
| 14 |
Kaija‐Leena Kolho, Henrik Alfthan, Esa Hämäläinen. Effect of Bowel Cleansing for Colonoscopy on Fecal Calprotectin Levels in Pediatric Patients. Journal of Pediatric Gastroenterology and Nutrition 2012; 55(6): 751 doi: 10.1097/MPG.0b013e31825f4c77
|
| 15 |
Kaija-Leena Kolho, Alberto Pessia, Tytti Jaakkola, Willem M. de Vos, Vidya Velagapudi. Faecal and serum metabolomics in paediatric inflammatory bowel disease. Journal of Crohn's and Colitis 2016; : jjw158 doi: 10.1093/ecco-jcc/jjw158
|
| 16 |
Rebecka Ventin-Holmberg, Miikka Höyhtyä, Schahzad Saqib, Katri Korpela, Anne Nikkonen, Anne Salonen, Willem M. de Vos, Kaija-Leena Kolho. The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-10548-7
|
| 17 |
Kaija-Leena Kolho, Elsa Valtonen, Hanne Rintamäki, Erkki Savilahti. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2012; 47(8-9): 951 doi: 10.3109/00365521.2012.699549
|
| 18 |
Anne-Claire Frin, Jérôme Filippi, Gilles Boschetti, Bernard Flourie, Jocelyne Drai, Patricia Ferrari, Xavier Hebuterne, Stéphane Nancey. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Digestive and Liver Disease 2017; 49(1): 11 doi: 10.1016/j.dld.2016.09.001
|
| 19 |
A. A. Kamalova, G. A. Garina, I. Kh. Valeeva, A. R. Gaifutdinova. Fecal calprotectin as a marker of inflammatory bowel diseases. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2023; 68(5): 138 doi: 10.21508/1027-4065-2023-68-5-138-143
|
| 20 |
Hana Manceau, Valérie Chicha-Cattoir, Hervé Puy, Katell Peoc’h. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clinical Chemistry and Laboratory Medicine (CCLM) 2017; 55(4) doi: 10.1515/cclm-2016-0522
|
| 21 |
Hui Won Jang, Hyun Sook Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intestinal Research 2016; 14(4): 305 doi: 10.5217/ir.2016.14.4.305
|
| 22 |
Erwin Dreesen, Ann Gils. Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. Therapeutic Drug Monitoring 2019; 41(2): 131 doi: 10.1097/FTD.0000000000000571
|
| 23 |
Kaija-Leena Kolho, Taina Sipponen, Elsa Valtonen, Erkki Savilahti. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. International Journal of Colorectal Disease 2014; 29(1): 43 doi: 10.1007/s00384-013-1775-9
|
| 24 |
Current World Literature. Current Opinion in Rheumatology 2012; 24(5): 586 doi: 10.1097/BOR.0b013e32835793df
|
| 25 |
Emanuel Burri, Christoph Beglinger. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Review of Gastroenterology & Hepatology 2014; 8(2): 197 doi: 10.1586/17474124.2014.869476
|
| 26 |
Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo, Sami Hoque. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment 2016; 20(39): 1 doi: 10.3310/hta20390
|
| 27 |
E Nissilä, K Korpela, A I Lokki, R Paakkanen, S Jokiranta, W M de Vos, M-L Lokki, K-L Kolho, S Meri. C4Bgene influences intestinal microbiota through complement activation in patients with paediatric-onset inflammatory bowel disease. Clinical and Experimental Immunology 2017; 190(3): 394 doi: 10.1111/cei.13040
|
| 28 |
Ivana Copova, Ondrej Hradsky, Kristyna Zarubova, Lucie Gonsorcikova, Kristyna Potuznikova, Tereza Lerchova, Jiri Nevoral, Jiri Bronsky. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease. European Journal of Pediatrics 2018; 177(11): 1685 doi: 10.1007/s00431-018-3228-5
|
| 29 |
Carmen Ribes Koninckx, Ester Donat, Marc A. Benninga, Ilse J. Broekaert, Frederic Gottrand, Kaija‐Leena Kolho, Paolo Lionetti, Erasmo Miele, Rok Orel, Alexandra Papadopoulou, Corina Pienar, Michela G. Schäppi, Michael Wilschanski, Nikhil Thapar. The Use of Fecal Calprotectin Testing in Paediatric Disorders. Journal of Pediatric Gastroenterology and Nutrition 2021; 72(4): 617 doi: 10.1097/MPG.0000000000003046
|
| 30 |
Johanna Lehtomäki, Anne Nikkonen, Laura Merras-Salmio, Pauliina Hiltunen, Kaija-Leena Kolho. Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2022; 57(1): 31 doi: 10.1080/00365521.2021.1977843
|
| 31 |
Emily K. Wright, Peter De Cruz, Richard Gearry, Andrew S. Day, Michael A. Kamm. Fecal Biomarkers in the Diagnosis and Monitoring of Crohnʼs Disease. Inflammatory Bowel Diseases 2014; 20(9): 1668 doi: 10.1097/MIB.0000000000000087
|
| 32 |
Kaija-Leena Kolho, Dan Turner. Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis. ISRN Gastroenterology 2013; 2013: 1 doi: 10.1155/2013/179024
|
| 33 |
Anu Haaramo, Kaija-Leena Kolho, Anne Pitkäranta, Mervi Kanerva. A 30-year follow-up study of patients with Melkersson–Rosenthal syndrome shows an association to inflammatory bowel disease. Annals of Medicine 2019; 51(2): 149 doi: 10.1080/07853890.2019.1591634
|
| 34 |
Kaija-Leena Kolho. Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Frontiers in Pediatrics 2021; 8 doi: 10.3389/fped.2020.623689
|
| 35 |
Frank M Ruemmele, Jeffrey S Hyams, Anthony Otley, Anne Griffiths, Kaija-Leena Kolho, Jorge Amil Dias, Arie Levine, Johanna C Escher, Jan Taminiau, Gabor Veres, Jean-Frederic Colombel, Séverine Vermeire, David C Wilson, Dan Turner. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2015; 64(3): 438 doi: 10.1136/gutjnl-2014-307008
|
| 36 |
Anu Haaramo, Heikki Alapulli, Liisa Aine, Ulla Saarnisto, Jetta Tuokkola, Tarja Ruuska, Taina Sipponen, Anne Pitkäranta, Kaija‐Leena Kolho. Detailed Follow‐up Study of Pediatric Orofacial Granulomatosis Patients. Journal of Pediatric Gastroenterology and Nutrition 2017; 65(4): 388 doi: 10.1097/MPG.0000000000001554
|
| 37 |
Maria Hemming-Harlo, Laura Merras-Salmio, Anne Nikkonen, Kaija-Leena Kolho. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting. European Journal of Pediatrics 2023; 183(1): 313 doi: 10.1007/s00431-023-05255-y
|
| 38 |
Laura Merras‐Salmio, Kaija‐Leena Kolho. Golimumab Therapy in Six Patients With Severe Pediatric Onset Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition 2016; 63(3): 344 doi: 10.1097/MPG.0000000000001165
|
| 39 |
Anu Haaramo, Heikki Alapulli, Liisa Aine, Jetta Tuokkola, Ulla Saarnisto, Risto P. Roine, Anne Pitkäranta, Kaija-Leena Kolho. Oral and Otorhinolaryngological Findings in Adults Who Were Diagnosed With Pediatric Onset Crohn’s Disease. Journal of Clinical Gastroenterology 2019; 53(7): e269 doi: 10.1097/MCG.0000000000001074
|
| 40 |
Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh. Early Serum Infliximab Levels in Pediatric Ulcerative Colitis. Frontiers in Pediatrics 2021; 9 doi: 10.3389/fped.2021.668978
|
| 41 |
Taina Sipponen, Kaija-Leena Kolho. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015; 50(1): 74 doi: 10.3109/00365521.2014.987809
|
| 42 |
Kaija-Leena Kolho, Taina Sipponen. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2014; 49(4): 434 doi: 10.3109/00365521.2014.886719
|
| 43 |
Kaija-Leena Kolho, Antti Ainamo. Progress in the treatment and outcome of pediatric inflammatory bowel disease patients. Expert Review of Clinical Immunology 2016; 12(12): 1337 doi: 10.1080/1744666X.2016.1201422
|
| 44 |
Taina Sipponen. Diagnostics and Prognostics of Inflammatory Bowel Disease with Fecal Neutrophil-Derived Biomarkers Calprotectin and Lactoferrin. Digestive Diseases 2013; 31(3-4): 336 doi: 10.1159/000354689
|
| 45 |
Kaija-Leena Kolho, Katri Korpela, Tytti Jaakkola, Madharasi V A Pichai, Erwin G Zoetendal, Anne Salonen, Willem M de Vos. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. American Journal of Gastroenterology 2015; 110(6): 921 doi: 10.1038/ajg.2015.149
|
| 46 |
Darla R. Shores, Allen D. Everett. Children as Biomarker Orphans: Progress in the Field of Pediatric Biomarkers. The Journal of Pediatrics 2018; 193: 14 doi: 10.1016/j.jpeds.2017.08.077
|
| 47 |
Tarja Mälkönen, Anne Wikström, Kaarina Heiskanen, Laura Merras-Salmio, Harri Mustonen, Taina Sipponen, Kaija-Leena Kolho. Skin Reactions During Anti-TNFα Therapy for Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2014; 20(8): 1309 doi: 10.1097/MIB.0000000000000088
|
| 48 |
Anne Nikkonen, Kaija‐Leena Kolho. Infliximab and its biosimilar produced similar first‐year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatrica 2020; 109(4): 836 doi: 10.1111/apa.15026
|
| 49 |
Cary M. Qualia, Athos Bousvaros. Advances in Pediatric IBD. Current Pediatrics Reports 2013; 1(3): 206 doi: 10.1007/s40124-013-0020-x
|